» Articles » PMID: 22938409

SiRNA-mediated Silencing of Notch-1 Enhances Docetaxel Induced Mitotic Arrest and Apoptosis in Prostate Cancer Cells

Overview
Specialty Oncology
Date 2012 Sep 4
PMID 22938409
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Notch is an important signaling pathway that regulates cell fate, stem cell maintenance and the initiation of differentiation in many tissues. It has been reported that activation of Notch-1 contributes to tumorigenesis. However, whether Notch signaling might have a role in chemoresistance of prostate cancer is unclear. This study aimed to investigate the effects of Notch-1 silencing on the sensitivity of prostate cancer cells to docetaxel treatment.

Methods: siRNA against Notch-1 was transfected into PC-3 prostate cancer cells. Proliferation, apoptosis and cell cycle distribution were examined in the presence or absence of docetaxel by MTT and flow cytometry. Expression of p21(waf1/cip1) and Akt as well as activation of Akt in PC-3 cells were detected by Western blot and Real-time PCR.

Results: Silencing of Notch-1 promoted docetaxel induced cell growth inhibition, apoptosis and cell cycle arrest in PC-3 cells. In addition, these effects were associated with increased p21(waf1/cip1) expression and decreased Akt expression and activation in PC-3 cells.

Conclusion: Notch-1 promotes chemoresistance of prostate cancer and could be a potential therapeutic target.

Citing Articles

Signaling pathways in colorectal cancer implications for the target therapies.

Song Y, Chen M, Wei Y, Ma X, Shi H Mol Biomed. 2024; 5(1):21.

PMID: 38844562 PMC: 11156834. DOI: 10.1186/s43556-024-00178-y.


Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.

Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A Cancer Metastasis Rev. 2024; 43(1):229-260.

PMID: 38374496 DOI: 10.1007/s10555-024-10168-9.


An overview of natural products that modulate the expression of non-coding RNAs involved in oxidative stress and inflammation-associated disorders.

Ngum J, Tatang F, Toumeni M, Nguengo S, Simo U, Mezajou C Front Pharmacol. 2023; 14:1144836.

PMID: 37168992 PMC: 10165025. DOI: 10.3389/fphar.2023.1144836.


Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma.

Laface C, Ranieri G, Maselli F, Ambrogio F, Foti C, Ammendola M Cancers (Basel). 2023; 15(3).

PMID: 36765612 PMC: 9913568. DOI: 10.3390/cancers15030654.


Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives.

Zhdanovskaya N, Firrincieli M, Lazzari S, Pace E, Scribani Rossi P, Felli M Cancers (Basel). 2021; 13(20).

PMID: 34680255 PMC: 8533696. DOI: 10.3390/cancers13205106.